Dublin, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The "Antimicrobial Susceptibility Testing Market by Product (Manual, Automated Susceptibility Testing System), Type (Antibacterial, Antifungal), Application (Clinical Diagnostics), Method (ETEST, Disk Diffusion), End-User - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.
The antimicrobial susceptibility testing market is projected to reach USD 4.2 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 5.5% during the forecast period.
Growth of the market is mainly attributed to the technological advancements; increasing incidences of infectious diseases, and growing public and private investments, funding, and grants are driving the global antimicrobial susceptibility testing market. However, complex regulatory frameworks that delay the approval of new microbial susceptibility tests is expected to challenge market growth to a certain extent.
In terms of products, automated laboratory instruments segment to register significant growth during the forecast period.
Based on the product, the antimicrobial susceptibility testing market is segmented into automated laboratory instruments, manual antimicrobial susceptibility testing products, culture and growth media, and consumables. Significant growth of the segment is attributed to the ongoing trend of laboratory automation among clinical laboratories, advantages offered by automated AST instruments over manual susceptibility instruments, and technological advancements in the market. Automated instruments offer a wide range of advantages over manual susceptibility testing products, such as reduced labor cost, shortened incubation time, and large-volume sample handling. These advantages offered by the automated systems have led to the growth of this segment.
Clinical diagnostics application segment is expected to witness the highest growth in the AST market, during the forecast period.
Based on application, the antimicrobial susceptibility testing market has been segmented into the antimicrobial susceptibility testing market is segmented into clinical diagnostics, drug discovery and development, epidemiology, and other applications. The growth in this market is attributed to the rising prevalence of infectious diseases, increasing incidence of HAIs, large target patient population base (especially in emerging countries), the growing procedural volume of clinical diagnostic tests, rising emphasis on effective and early disease diagnosis across major markets, and the introduction of various technologically advanced susceptibility testing products.
Diagnostic laboratories and hospitals segment is expected to account for the largest share of the AST market, by the end user
On the basis of end-users, the antimicrobial susceptibility testing market has been segmented into diagnostic laboratories and hospitals, pharmaceutical and biotechnology companies, contract research organizations (CROs), and research and academic institutes. The growth of this segment is attributed to the significant number of antibacterial, antiparasitic, and antifungal tests procedures performed in diagnostic laboratories and hospitals; and the growing number of hospitals across major markets. Moreover, a growing trend towards the utilization of rapid AST platforms and improving healthcare expenditure in emerging markets will further boost the growth of this segment in the coming years.
Asia Pacific market is expected to grow at the highest CAGR during the forecast period.
The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period majorly due to the heavy burden of infectious diseases, rising healthcare expenditure, and increasing research into AST. Apart from this, the rising number of biotechnology and pharmaceutical companies in the APAC region is expected to propel the market for antimicrobial susceptibility testing.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Antimicrobial Susceptibility Testing: Market Overview
4.2 Geographic Analysis: Antimicrobial Susceptibility Testing Market, by Product, 2020 vs 2025, (USD Million)
4.3 Manual Antimicrobial Susceptibility Testing Products Market, by Type, 2020 vs 2025, (USD Million)
4.4 Antimicrobial Susceptibility Testing Market, by Region and Type
4.5 Geographic Analysis: Antimicrobial Susceptibility Testing Market, by Method and Region, 2020 vs 2025, (USD Million)
4.6 Geographic Snapshot of the Antimicrobial Susceptibility Testing Market
5 Market Overview
5.2 Market Dynamics
18.104.22.168 Rising Incidence of Infectious Diseases Coupled with Epidemic & Pandemic Events
22.214.171.124 Increasing Funding, Research Grants, and Public-Private Investments in the Market
126.96.36.199 Technological Advancements
188.8.131.52 Growing Government Initiatives to Detect and Control Antimicrobial-Resistant Species
184.108.40.206 Emergence of Multidrug-Resistance Due to Drug Abuse
220.127.116.11 High Cost of Automated Id/AST Systems
18.104.22.168 Emerging Markets
22.214.171.124 Awareness Initiatives for Antimicrobial Resistance and Its Control
126.96.36.199 Complex Regulatory Frameworks That Delay Antimicrobial Testing Approvals
5.3 Impact of the COVID-19 on the Antimicrobial Susceptibility Testing Market
5.4 Ecosystem Analysis
5.5 Value Chain Analysis
5.6 Regulatory Analysis
5.6.1 North America
6 Antimicrobial Susceptibility Testing Market, by Product
6.2 Manual Antimicrobial Susceptibility Testing Products
6.3 Automated Laboratory Instruments
6.4 Culture and Growth Media
6.4.1 High Utilization of Disk Diffusion and Broth Dilution Methods to Drive the Segment Growth
7 Antimicrobial Susceptibility Testing Market, by Type
7.2 Antibacterial Susceptibility Testing
7.2.1 the Emergence of Multidrug-Resistance to Increase Adoption of Antibacterial Susceptibility Testing Products
7.3 Antifungal Susceptibility Testing
7.3.1 Increasing Candida and Aspergillus Species Fungal Infections Are Major Factors Driving Segment Growth
7.4 Antiparasitic Susceptibility Testing
7.4.1 Rising Initiatives to Create Awareness About Parasitic Infections to Drive Segment Growth for Products
7.5 Other Susceptibility Testing Types
7.5.1 Complexity Associated with Fastidious Pathogen Testing to Hamper the Growth of this Segment
8 Antimicrobial Susceptibility Testing Market, by Application
8.2 Clinical Diagnostics
8.2.1 Technological Advancements and Increasing Number of Susceptibility Tests Performed Drive Segment Growth
8.3 Drug Discovery and Development
8.3.1 Rising Adoption of Rapid AST Solutions by Biopharmaceutical Companies to Drive Segment Growth
8.4.1 Outbreak of Pandemic and Epidemic Situations to Drive Demand for AST Products
8.5 Other Applications
8.5.1 Growing Adoption of AST Products for Bioterrorism Surveillance to Fuel Segment Growth
9 Antimicrobial Susceptibility Testing Market, by Method
9.2 Automated Antimicrobial Susceptibility Testing Instruments
9.2.1 Technological Advancements and Favorable Product Pipeline to Drive Segment Growth
9.3 Disk Diffusion
9.3.1 Rising Incidences of Urinary Tract Infections to Drive Segment Growth
9.4 Agar Dilution
9.4.1 Agar Dilution Helps Explore Drug Combinations for Combined Antibiotic Therapy
9.5 Etest Method
9.5.1 Uncertainties in Result Interpretation Hampers the Adoption of this Method
9.6 Genotypic Methods
9.6.1 Ongoing Clinical Trials and Upcoming Product Launches Support Segment Growth
10 Antimicrobial Susceptibility Testing Market, by End-user
10.2 Hospitals and Diagnostic Centers
10.2.1 High Prevalence of Infectious Diseases Coupled with the Rising Adoption of Rapid AST Solutions to Drive Segment Growth
10.3 Pharmaceutical and Biotechnology Companies
10.3.1 Increasing Number of Biopharmaceutical Companies to Support Segment Growth
10.4 Research & Academic Institutes
10.4.1 Growing Research Grants and Funding is Accelerating the Growth of this Segment
10.5 Contract Research Organizations
10.5.1 Clinical Trial Globalization and the Growing Number of Cros in Emerging Economies Drives Market Growth
11 Antimicrobial Susceptibility Testing Market, by Region
11.2 North America
11.5 Latin America
11.6 Middle East & Africa
12 Competitive Landscape
12.2 Market Share Analysis
12.3 Competitive Scenario
12.3.1 Product Launches and Approvals
12.3.3 Agreements and Collaborations
13 Company Evolution Matrix and Company Profiles
13.1 Competitive Evolution Matrix and Methodology
13.1.1 Competitive Leadership Mapping: Major Market Players (2019)
188.8.131.52 Visionary Leaders
184.108.40.206 Dynamic Differentiators
220.127.116.11 Emerging Companies
13.1.2 Competitive Leadership Mapping: Emerging Companies/Smes/Start-Ups (2019)
18.104.22.168 Progressive Companies
22.214.171.124 Starting Blocks
126.96.36.199 Responsive Companies
188.8.131.52 Dynamic Companies
13.2 Company Profiles
13.2.1 Biomerieux Sa
13.2.2 Becton, Dickinson and Company
13.2.3 Thermo Fisher Scientific
13.2.4 Danaher Corporation
13.2.5 Bio-Rad Laboratories, Inc.
13.2.7 Roche Diagnostics
13.2.8 Merck Kgaa
13.2.9 Accelerate Diagnostics, Inc.
13.2.10 Himedia Laboratories
13.2.11 Liofilchem S.R.L.
13.2.12 Alifax S.R.L.
13.2.13 Creative Diagnostics
13.2.16 Other Companies
184.108.40.206 Zhuhai Dl Biotech Co. Ltd.
220.127.116.11 Mast Group Ltd.
18.104.22.168 Genefluidics, Inc.
14.1 Discussion Guide
14.2 Knowledge Store: The Subscription Portal
14.3 Available Customizations
14.4 Related Reports
14.5 Author Details
For more information about this report visit https://www.researchandmarkets.com/r/9kei8j
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900